Navigation Links
SCOLR Pharma Welcomes Clem Calabrese as Director of Field Sales
Date:5/1/2012

BELLEVUE, Wash., May 1, 2012 /PRNewswire/ -- SCOLR Pharma, Inc. (OTCQB: SCLR) announced today that effective May 1, 2012 Clem Calabrese will be joining the SCOLR team as Director of Field Sales to lead our aggressive field sales & marketing activities.  Clem brings a wealth of field sales experience to SCOLR and will be primarily responsible for working with our existing sales staff, the Emerson Group and our retail customers in order to ensure we aggressively grow our sales while providing the utmost in customer service.

Clem brings over 35 years of Branded and Store Brand Sales & Marketing experience with Major Consumer Products Companies.

Stephen Turner, President and CEO of SCOLR, said: "We are excited to have Clem join the SCOLR team.  He is an impressive individual and will most assuredly provide us with additional sales opportunities as we continue to grow our consumer products sales.  The depth of his relationships and contacts within the industry will enable SCOLR to continue the momentum created with our CDT® Controlled Release Technology with retailers."

About SCOLR Pharma:

Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT® platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT® drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

Forward looking statements:                                              

Any statements made in this press release that relate to future plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward looking statements include statements regarding SCOLR's partners development of drug formulations, the results of a bioequivalence trials, anticipated future plans related to approval of drug formulations by the Food and Drug Administration, and the development and marketing of any drug formulations.  Factors that could cause these forward-looking statements to differ from actual results include adverse regulatory determinations related to trials, competitive factors related to drug products, economic factors including partner's ability to finance the development and commercialization of any product, and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission.  SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.

Contacts:
Investor Relations:                                             
SCOLR Pharma, Inc.                                            
425.368.1050


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharma, Inc. Provides Product Information on Website
2. SCOLR Pharma, Inc. Launches Cutting Edge Nutritional Products at Major Retailers in 2012
3. SCOLR Pharmas Partner to Commence Bioequivalence Study of Ondansetron
4. SCOLR Pharma, Inc. Announces Initial Shipments of its Nutritional Products
5. SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results
6. SCOLR Pharma, Inc. First Quarter 2011 Financial Results
7. SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference
8. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
9. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
10. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
11. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology:
(Date:6/27/2016)... Dublin, CA (PRWEB) , ... June 27, 2016 ... ... Community College District , the only authorized OSHA Training Institute Education Center headquartered ... illness by protecting their workers from extreme heat at their worksites. Employers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... health professionals, announced today its affiliation with Tennessee Counseling Association. This ... the network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
Breaking Medicine News(10 mins):